Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDH1 siRNA
- Development stage
- Preclinical
- Lead developer
- Case Western Reserve University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
IDH1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the isocitrate dehydrogenase 1 (IDH1) gene. IDH1 is a key metabolic enzyme that converts isocitrate to alpha-ketoglutarate (αKG) while reducing NADP+ to NADPH. In melanoma, wild-type IDH1 is frequently overexpressed and serves as a major source of cytosolic NADPH, which is essential for maintaining redox homeostasis and protecting cells from oxidative stress under metabolic or hypoxic conditions. By silencing IDH1, this siRNA reduces the availability of NADPH and glutathione (GSH), leading to an accumulation of reactive oxygen species (ROS) and mitochondrial dysfunction. Research indicates that IDH1 silencing impairs the proliferation and migration of melanoma cells and increases their sensitivity to DNA-alkylating agents like temozolomide (TMZ), suggesting its potential as a therapeutic strategy for chemoresistant tumors.
- Other names
- IDH1 small interfering RNAIDH-1 small interfering RNAIDH 1 small interfering RNAsiRNA targeting IDH1isocitrate dehydrogenase 1 siRNA
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)Isocitrate dehydrogenase 1 (NADP+), soluble mRNA
Beyond the preview
Go deeper on IDH1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDH1 siRNA.